BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down

Reuters01-23

** Shares of drug developer ImmunityBio IBRX.O fall 3% to $7.13 premarket

** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached

** Co says its experimental chemo-free combo of Anktiva and CAR‑NK cells aims to help the immune system fight the tumor

** Anktiva is an immune‑activating protein and part of a chemo‑free combo being tested in recurrent glioblastoma

** Patients showed improved immune cell counts after one treatment cycle - IBRX

** IBRX fell ~23% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605340894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605340894","market":"fut","top_or_hot":-1,"title":"BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down</title></head><body><p>** Shares of drug developer ImmunityBio <span>IBRX.O</span> fall 3% to $7.13 premarket </p><p>** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached </p><p>** Co says its experimental chemo-free combo of Anktiva and CAR‑NK cells aims to help the immune system fight the tumor</p><p>** Anktiva is an immune‑activating protein and part of a chemo‑free combo being tested in recurrent glioblastoma</p><p>     ** Patients showed improved immune cell counts after one treatment cycle - IBRX</p><p>** IBRX fell ~23% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-23 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down</title></head><body><p>** Shares of drug developer ImmunityBio <span>IBRX.O</span> fall 3% to $7.13 premarket </p><p>** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached </p><p>** Co says its experimental chemo-free combo of Anktiva and CAR‑NK cells aims to help the immune system fight the tumor</p><p>** Anktiva is an immune‑activating protein and part of a chemo‑free combo being tested in recurrent glioblastoma</p><p>     ** Patients showed improved immune cell counts after one treatment cycle - IBRX</p><p>** IBRX fell ~23% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nL4N3YO16M:1","article_id":"2605340894","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605340894","pubTimestamp":1769174849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down** Shares of drug developer ImmunityBio IBRX.O fall 3% to $7.13 premarket ** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached ** Co says its experimental chemo-free combo of Anktiva and CARNK cells aims to help the immune system fight the tumor** Anktiva is an immuneactivating protein and part of a chemofree combo being tested in recurrent glioblastoma     ** Patients showed improved immune cell counts after one treatment cycle - IBRX** IBRX fell ~23% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"BUZZ-ImmunityBio发布早期脑癌治疗试验数据；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BUZZ-ImmunityBio releases early brain cancer treatment trial data; shares down** Shares of drug developer ImmunityBio IBRX.O fall 3% to $7.13 premarket ** Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached ** Co says its experimental chemo-free combo of Anktiva and CAR‑NK cells aims to help the immune system fight the tumor** Anktiva is an immune‑activating protein and part of a chemo‑free combo being tested in recurrent glioblastoma     ** Patients showed improved immune cell counts after one treatment cycle - IBRX** IBRX fell ~23% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605340894","isCrawlerRequest":true}